Physician profile
John Thomas Fletcher
NPI 1114006947
$7,868.12
in general payments reported to CMS, 2019-2025
37 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $355 · 2021: $817 · 2022: $1,203 · 2023: $1,328 · 2024: $1,765 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,082.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,563.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,008.83 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $433.72 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $363.35 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $321.72 | 2022-2025 | |
| Ardelyx, INC. | $252.11 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $236.38 | 2024-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $223.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $212.15 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.29 | 2019-2025 | Xifaxan, Trulance |
| Vivus LLC | $153.76 | 2023-2025 | Qsymia |
| Lilly USA, LLC | $143.71 | 2024-2025 | Omvoh |
| Evoke Pharma, INC. | $142.83 | 2021-2025 | Gimoti |
| Phathom Pharmaceuticals, INC. | $139.41 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $133.56 | 2020-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $129.94 | 2019-2024 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $114.62 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $110.87 | 2019-2025 | Suflave |
| Celgene Corporation | $105.17 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $100.19 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $92.31 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $92.04 | 2022 | |
| Medtronic, INC. | $86.33 | 2024-2025 | Pillcam, Gi Genius |
| Pfizer INC. | $68.79 | 2024-2025 | |
| Celltrion USA INC. | $61.00 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $50.68 | 2019-2023 | Linzess |
| Myriad Genetic Laboratories, INC. | $49.04 | 2023-2025 | Myrisk, Precisetumor |
| Alnylam Pharmaceuticals INC. | $48.23 | 2024 | Givlaari |
| Allergan, INC. | $48.15 | 2019-2020 | |
| Axonics, INC. | $31.17 | 2021 | |
| Ferring Pharmaceuticals INC. | $30.76 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $25.94 | 2024 | Rapide Balloons |
| Cumberland Pharmaceuticals, INC. | $24.72 | 2019 | |
| Ethicon US, LLC | $20.45 | 2019 | |
| Echosens North America, INC. | $14.29 | 2025 | Fibroscan |
| Amag Pharmaceuticals, INC. | $14.23 | 2021 | |
| Redhill Biopharma INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.